β-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation
暂无分享,去创建一个
J. Reis-Filho | M. Lacroix-Triki | R. Natrajan | A. Mackay | M. Arnedos | K. Savage | M. Lambros | F. Geyer
[1] Robin L. Jones,et al. PPM1D gene amplification and overexpression in breast cancer: a qRT-PCR and chromogenic in situ hybridization study , 2010, Modern Pathology.
[2] I. Ellis,et al. β-catenin/Wnt signalling pathway in fibromatosis, metaplastic carcinomas and phyllodes tumours of the breast , 2010, Modern Pathology.
[3] I. Tomlinson,et al. Nuclear β‐catenin expression and Wnt signalling: in defence of the dogma , 2010, The Journal of pathology.
[4] O. Olopade,et al. Stem Cells , Tissue Engineering and Hematopoietic Elements Wnt /-Catenin Pathway Activation Is Enriched in Basal-Like Breast Cancers and Predicts Poor Outcome , 2010 .
[5] A. Ashworth,et al. An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers , 2010, Breast Cancer Research and Treatment.
[6] S. O'toole,et al. Cytoplasmic Localization of β-Catenin is a Marker of Poor Outcome in Breast Cancer Patients , 2010, Cancer Epidemiology, Biomarkers & Prevention.
[7] B. Kreike,et al. Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis , 2009, Breast Cancer Research and Treatment.
[8] Nicholas J. Wang,et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. , 2009, Cancer research.
[9] A. Ashworth,et al. Tiling Path Genomic Profiling of Grade 3 Invasive Ductal Breast Cancers , 2009, Clinical Cancer Research.
[10] P. Argani,et al. Most Basal-like Breast Carcinomas Demonstrate the Same Rb−/p16+ Immunophenotype as the HPV-related Poorly Differentiated Squamous Cell Carcinomas Which They Resemble Morphologically , 2009, The American journal of surgical pathology.
[11] I. Ellis,et al. Patho-biological aspects of basal-like breast cancer , 2009, Breast Cancer Research and Treatment.
[12] O. Sieber,et al. APC and the three-hit hypothesis , 2009, Oncogene.
[13] A. Lazar,et al. Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. , 2008, The American journal of pathology.
[14] Robin L. Jones,et al. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients , 2008, Breast Cancer Research and Treatment.
[15] A. Ashworth,et al. Genomic and immunophenotypical characterization of pure micropapillary carcinomas of the breast , 2008, The Journal of pathology.
[16] J. Reis-Filho,et al. Nestin is expressed in basal-like and triple negative breast cancers , 2008, Journal of Clinical Pathology.
[17] T. Giordano,et al. Genetic Changes of Wnt Pathway Genes Are Common Events in Metaplastic Carcinomas of the Breast , 2008, Clinical Cancer Research.
[18] Robin L. Jones,et al. Distribution and significance of caveolin 2 expression in normal breast and invasive breast cancer: an immunofluorescence and immunohistochemical analysis , 2008, Breast Cancer Research and Treatment.
[19] Alan Mackay,et al. Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines , 2008, Laboratory Investigation.
[20] Gema Moreno-Bueno,et al. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. , 2008, Cancer research.
[21] J. Reis-Filho,et al. Reduction of E-cadherin expression is associated with non-lobular breast carcinomas of basal-like and triple negative phenotype , 2007, Journal of Clinical Pathology.
[22] H. Juan,et al. Molecular signatures of metaplastic carcinoma of the breast by large-scale transcriptional profiling: identification of genes potentially related to epithelial–mesenchymal transition , 2007, Oncogene.
[23] Robin L. Jones,et al. Caveolin 1 Is Overexpressed and Amplified in a Subset of Basal-like and Metaplastic Breast Carcinomas: A Morphologic, Ultrastructural, Immunohistochemical, and In situ Hybridization Analysis , 2007, Clinical Cancer Research.
[24] S. Lakhani,et al. Metaplastic breast carcinomas are basal‐like tumours , 2006, Histopathology.
[25] David L Rimm,et al. Quantitative in situ analysis of beta-catenin expression in breast cancer shows decreased expression is associated with poor outcome. , 2006, Cancer research.
[26] Robin L. Jones,et al. Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis , 2006, Modern Pathology.
[27] A. Gown,et al. Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.
[28] D. Rimm,et al. β‐Catenin and p53 analyses of a breast carcinoma tissue microarray , 2004, Cancer.
[29] M. Romeih,et al. Wnt signaling in hepatocellular carcinoma: Analysis of mutation and expression of beta‐catenin, T‐cell factor‐4 and glycogen synthase kinase 3‐beta genes , 2003, Journal of gastroenterology and hepatology.
[30] K. B. Pedersen,et al. Expression of S100A4, E-cadherin, α- and β-catenin in breast cancer biopsies , 2002, British Journal of Cancer.
[31] M. Hung,et al. β-catenin interacts with and inhibits NF-κB in human colon and breast cancer , 2002 .
[32] S. Hirohashi,et al. Target disruption of the mutant β-catenin gene in colon cancer cell line HCT116: preservation of its malignant phenotype , 2002, Oncogene.
[33] S. Wong,et al. Expression of frizzled‐related protein and Wnt‐signalling molecules in invasive human breast tumours , 2002, The Journal of pathology.
[34] D. Miles,et al. Retention of the expression of E‐cadherin and catenins is associated with shorter survival in grade III ductal carcinoma of the breast , 2001, The Journal of pathology.
[35] M. Hung,et al. β-Catenin, a novel prognostic marker for breast cancer: Its roles in cyclin D1 expression and cancer progression , 2000 .
[36] A. Børresen-Dale,et al. Re‐expression of E‐cadherin, α‐catenin and β‐catenin, but not of γ‐catenin, in metastatic tissue from breast cancer patients , 2000 .
[37] I. Ellis,et al. Pathological prognostic factors in breast cancer. , 1999, Critical reviews in oncology/hematology.
[38] Y. Nakamura,et al. Transformation and morphological changes of murine L cells by transfection with a mutated form of beta-catenin. , 1999, Cancer research.
[39] C K Osborne,et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] Boecker,et al. Immunophenotypic and prognostic analysis of E‐cadherin and β‐catenin expression during breast carcinogenesis and tumour progression: a comparative study with CD44 , 1999, Histopathology.
[41] A. Sparks,et al. Identification of c-MYC as a target of the APC pathway. , 1998, Science.
[42] A. Børresen-Dale,et al. E‐cadherin and α‐, β‐, and γ‐catenin protein expression in relation to metastasis in human breast carcinoma , 1998 .
[43] Bert Vogelstein,et al. Mutational Analysis of the APC/β-Catenin/Tcf Pathway in Colorectal Cancer , 1998 .
[44] T. Iwama,et al. Coexistence of somatic and germ-line mutations of APC gene in desmoid tumors from patients with familial adenomatous polyposis. , 1993, Cancer research.
[45] I. Ellis,et al. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.
[46] G. Azabdaftari,et al. Refinement of breast cancer classification by molecular characterization of histological special types , 2009 .
[47] S. Singletary,et al. Breast Cancer Staging: Working With the Sixth Edition of the AJCC Cancer Staging Manual , 2006, CA: a cancer journal for clinicians.
[48] Minoti Hiremath,et al. Beta-catenin and Tcfs in mammary development and cancer. , 2003, Journal of mammary gland biology and neoplasia.
[49] M. Hung,et al. beta-catenin interacts with and inhibits NF-kappa B in human colon and breast cancer. , 2002, Cancer cell.
[50] A. Krasinskas,et al. Fibromatosis of the breast and mutations involving the APC/beta-catenin pathway. , 2002, Human pathology.
[51] A. Krasinskas,et al. Fibromatosis of the breast and mutations involving the APC/β-catenin pathway , 2002 .
[52] M. Hung,et al. Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[53] A. Børresen-Dale,et al. Re-expression of E-cadherin, alpha-catenin and beta-catenin, but not of gamma-catenin, in metastatic tissue from breast cancer patients [seecomments]. , 2000, The Journal of pathology.
[54] F. McCormick,et al. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. , 1999, Nature.
[55] A. Sparks,et al. Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. , 1998, Cancer research.
[56] A. Børresen-Dale,et al. E-cadherin and alpha-, beta-, and gamma-catenin protein expression in relation to metastasis in human breast carcinoma. , 1998, The Journal of pathology.
[57] D. Rimm,et al. The expression of p120ctn protein in breast cancer is independent of alpha- and beta-catenin and E-cadherin. , 1998, The American journal of pathology.
[58] H. Höfler,et al. No evidence for mutations in the alpha- and beta-catenin genes in human gastric and breast carcinomas. , 1996, Cancer research.
[59] H. Höfler,et al. No Evidence for Mutations in the α- and β-Catenin Genes in Human Gastric and Breast Carcinomas , 1996 .